BIO-TECHNE Corp
TECH- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000842023
No open-market purchases or sales by BIO-TECHNE Corp insiders were filed in the last 90 days; 597 institutions reported holding it in 13F filings for Q2 2026, worth $12.3B in total; 3 superinvestors hold it, including Maverick Capital and Weitz Investment Management.
Q3 2025 vs. Q2 2025
How the institutions holding BIO-TECHNE Corp changed between Q2 2025 and Q3 2025.
All holders in Q3 2025All holders in Q2 2025
| Measure | Q2 2025 | Of which not filed for Q3 2025 | Q3 2025 | Change |
|---|---|---|---|---|
| Holders | 556 | 7 | 577 | +28 |
| Shares | 158.6M | 1.94M | 158.9M | +2.21M (+1.4%) |
| Value | $8.16B | $99.9M | $8.84B | +$776.6M (+9.6%) |
7 institutions that held it in Q2 2025 haven't filed for Q3 2025 yet. Not filing isn't selling, so the changes leave them out.
New holders (97)
Institutions that held BIO-TECHNE Corp at the end of Q3 2025 but not at the end of Q2 2025.
Sold out (69)
Institutions that held BIO-TECHNE Corp at the end of Q2 2025 and filed for Q3 2025 without it.
Not filed for Q3 2025 yet (7)
Institutions that held BIO-TECHNE Corp at the end of Q2 2025 and haven't filed a 13F for Q3 2025. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2025 | Value, Q2 2025 |
|---|---|---|
| Norges Bank | 1,909,395 | $98.2M |
| CIBC World Markets Corp | 13,197 | $679.0K |
| Avantax Advisory Services, Inc. | 13,056 | $671.7K |
| E Fund Management Co., Ltd. | 5,497 | $282.8K |
| First Horizon Advisors, Inc. | 868 | $44.7K |
| Centricity Wealth Management, LLC | 52 | $2.67K |
| Parkworth Wealth Management, Inc. | 11 | $566 |